133,183 Shares in Indivior PLC (NASDAQ:INDV) Purchased by Kazazian Asset Management LLC

Kazazian Asset Management LLC acquired a new position in Indivior PLC (NASDAQ:INDV) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 133,183 shares of the company’s stock, valued at approximately $1,706,000. Indivior makes up approximately 1.3% of Kazazian Asset Management LLC’s holdings, making the stock its 20th biggest position. Kazazian Asset Management LLC owned about 0.10% of Indivior at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Iron Triangle Partners LP bought a new stake in shares of Indivior during the 3rd quarter valued at about $8,243,000. Krensavage Asset Management LLC bought a new stake in shares of Indivior during the 3rd quarter valued at about $6,843,000. Stonepine Capital Management LLC bought a new stake in shares of Indivior during the 3rd quarter valued at about $2,632,000. Clark Estates Inc. NY bought a new stake in shares of Indivior during the 3rd quarter valued at about $2,477,000. Finally, Petrus Trust Company LTA bought a new stake in shares of Indivior during the 3rd quarter valued at about $1,251,000. 60.33% of the stock is currently owned by institutional investors.

Indivior Trading Down 2.5 %

Shares of NASDAQ:INDV opened at $9.74 on Wednesday. The stock has a 50 day moving average of $10.55 and a 200 day moving average of $10.45. The company has a market cap of $1.34 billion, a PE ratio of -27.83 and a beta of 0.82. Indivior PLC has a 12-month low of $7.33 and a 12-month high of $22.53.

Indivior (NASDAQ:INDV) last announced its quarterly earnings data on Thursday, February 20th. The company reported $0.32 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.32. The company had revenue of $298.00 million during the quarter, compared to the consensus estimate of $262.35 million. Indivior had a negative return on equity of 241.73% and a negative net margin of 3.96%. Equities research analysts predict that Indivior PLC will post 1.22 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. Rodman & Renshaw assumed coverage on Indivior in a research note on Tuesday, January 28th. They set a “buy” rating and a $16.00 price target for the company. RODMAN&RENSHAW upgraded Indivior to a “strong-buy” rating in a research note on Tuesday, January 28th. Finally, Piper Sandler cut their price target on Indivior from $16.00 to $13.00 and set an “overweight” rating for the company in a research note on Thursday, March 6th.

Indivior Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.